{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Foncologypodcast.simplecast.com%2Fepisodes%2Fesgo-2022-Bvb4CIz2","width":444,"version":"1.0","type":"rich","title":"Expert Thoughts on Studies of Interest Presented at the 2022 ESGO Annual Meeting on Gynecologic Cancers","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/26d7523c-7315-48a0-9da6-29d252d3ce90/464dcccb-a6bc-4460-b506-ff3c35437999/pod488-gyn-annual-meetings-cf-podcasticon-esgo.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/d2764ece-48a3-486c-b52d-d7ae59c3f15d\" height=\"200\" width=\"100%\" title=\"Expert Thoughts on Studies of Interest Presented at the 2022 ESGO Annual Meeting on Gynecologic Cancers\" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"In this podcast episode, listen to Prof Isabelle Ray-Coquard, MD, PhD, and Ignace Vergote, MD, PhD, share their thoughts on trials of interest including novel HRD testing for ovarian cancer, OS results from ARIEL3, and QoL outcomes for rare nonepithelial ovarian cancers following chemotherapy."}